Literature DB >> 29029808

Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension.

Csaba P Kovesdy1, Lawrence J Appel2, Morgan E Grams2, Lisa Gutekunst3, Peter A McCullough4, Biff F Palmer5, Bertram Pitt6, Dominic A Sica7, Raymond R Townsend8.   

Abstract

While much emphasis, and some controversy, centers on recommendations for sodium intake, there has been considerably less interest in recommendations for dietary potassium intake, in both the general population and patients with medical conditions, particularly acute and chronic kidney disease. Physiology literature and cohort studies have noted that the relative balance in sodium and potassium intakes is an important determinant of many of the sodium-related outcomes. A noteworthy characteristic of potassium in clinical medicine is the extreme concern shared by many practitioners when confronted by a patient with hyperkalemia. Fear of this often asymptomatic finding limits enthusiasm for recommending potassium intake and often limits the use of renin-angiotensin-aldosterone system blockers in patients with heart failure and chronic kidney diseases. New agents for managing hyperkalemia may alter the long-term management of heart failure and the hypertension, proteinuria, and further function loss in chronic kidney diseases. In this jointly sponsored effort between the American Society of Hypertension and the National Kidney Foundation, 3 panels of researchers and practitioners from various disciplines discussed and summarized current understanding of the role of potassium in health and disease, focusing on cardiovascular, nutritional, and kidney considerations associated with both hypo- and hyperkalemia.
Copyright © 2017 Published jointly in American Journal of Kidney Diseases and the Journal of the American society of Hypertension by Elsevier Inc, on behalf of the National Kidney Foundation and the American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Potassium; cardiovascular disease (CVD); chronic kidney disease (CKD); dietary intake; heart disease; hyperkalemia; hypokalemia; patiromer calcium (RLY5016); potassium homeostasis; potassium secretion; renal excretion; review; sodium zirconium cyclosilicate (ZS-9); sodium-polystyrene sulfonate

Mesh:

Substances:

Year:  2017        PMID: 29029808     DOI: 10.1053/j.ajkd.2017.09.003

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   11.072


  21 in total

1.  A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.

Authors:  Steven Fishbane; Martin Ford; Masafumi Fukagawa; Kieran McCafferty; Anjay Rastogi; Bruce Spinowitz; Konstantin Staroselskiy; Konstantin Vishnevskiy; Vera Lisovskaja; Ayman Al-Shurbaji; Nicolas Guzman; Sunil Bhandari
Journal:  J Am Soc Nephrol       Date:  2019-06-14       Impact factor: 10.121

Review 2.  Potassium Homeostasis, Chronic Kidney Disease, and the Plant-Enriched Diets.

Authors:  Biff F Palmer; Gates Colbert; Deborah J Clegg
Journal:  Kidney360       Date:  2020-01-08

3.  The association between serum glucose to potassium ratio on admission and short-term mortality in ischemic stroke patients.

Authors:  Yuzhao Lu; Xin Ma; Xiaobing Zhou; Yang Wang
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

4.  Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.

Authors:  Simon D Roger; Bruce S Spinowitz; Edgar V Lerma; Bhupinder Singh; David K Packham; Ayman Al-Shurbaji; Mikhail Kosiborod
Journal:  Am J Nephrol       Date:  2019-10-28       Impact factor: 3.754

5.  Rationale and Design of a Randomized Placebo-Controlled Clinical Trial Assessing the Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease.

Authors:  Martin Gritter; Liffert Vogt; Stanley M H Yeung; Rosa D Wouda; Christian R B Ramakers; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn
Journal:  Nephron       Date:  2018-06-29       Impact factor: 2.847

6.  Potassium Trajectories prior to Dialysis and Mortality following Dialysis Initiation in Patients with Advanced CKD.

Authors:  Ankur A Dashputre; Keiichi Sumida; Praveen K Potukuchi; Suryatapa Kar; Yoshitsugu Obi; Fridtjof Thomas; Miklos Z Molnar; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Nephron       Date:  2021-03-22       Impact factor: 2.847

7.  Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis.

Authors:  Keiichi Sumida; Ankur A Dashputre; Praveen K Potukuchi; Fridtjof Thomas; Yoshitsugu Obi; Miklos Z Molnar; Justin D Gatwood; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  J Am Soc Nephrol       Date:  2021-02-05       Impact factor: 10.121

8.  Association of Dyskalemias with Ischemic Stroke in Advanced Chronic Kidney Disease Patients Transitioning to Dialysis.

Authors:  Ankur A Dashputre; Keiichi Sumida; Fridtjof Thomas; Justin Gatwood; Oguz Akbilgic; Praveen K Potukuchi; Yoshitsugu Obi; Miklos Z Molnar; Elani Streja; Kamyar Kalantar Zadeh; Csaba P Kovesdy
Journal:  Am J Nephrol       Date:  2021-07-21       Impact factor: 4.605

9.  Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study.

Authors:  Paola Laureati; Yang Xu; Marco Trevisan; Lovisa Schalin; Illaria Mariani; Rino Bellocco; Manish M Sood; Peter Barany; Arvid Sjölander; Marie Evans; Juan J Carrero
Journal:  Nephrol Dial Transplant       Date:  2020-09-01       Impact factor: 5.992

Review 10.  Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.